Novartis investor demands board shake-up after record share drop on trial setbacks

A major Novartis shareholder is publicly calling for board changes after the company's shares experienced a record decline, triggered by clinical trial failures. The demand signals investor dissatisfaction with management and could lead to governance changes, though the specific trial setbacks and shareholder identity remain unspecified. This matters as it may pressure Novartis to alter strategy or leadership, with potential implications for its stock and the broader pharma sector.